Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zepatier in HCV-uninfected Kidney Transplant Recipients
NCT02781649Phase 4Completed
- Sponsor
- Johns Hopkins University
- Start
- Jul 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of grazoprevir in hepatitis C (HCV) (3 arms), sponsored by Johns Hopkins University. Primary endpoint: Number of Participants With Grade 3 or Higher Treatment-related Adverse Events. Started Jul 2016; status: completed.
02
Drugs
grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02781649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02781649.